Frontiers | Protein tyrosine phosphatase 1B in metabolic and cardiovascular diseases: from mechanisms to therapeutics

Frontiers | Protein tyrosine phosphatase 1B in metabolic and cardiovascular diseases: from mechanisms to therapeutics
REVIEW article
Front. Cardiovasc. Med.
, 22 August 2024
Sec. Cardiovascular Metabolism
Volume 11 - 2024 |
Published in
Frontiers in Cardiovascular Medicine
Cardiovascular Metabolism
2.9
impact factor
5.5
citescore
Part of a Research Topic
Obesity and Cardiovascular Disease
23k
views
articles
Edited by
Venkatesh Sundararajan
School of Medicine, West Virginia University, United States
Reviewed by
Sujith Rajan
Long Island School of Medicine, New York University, United States
Marcello Rota
New York Medical College, United States
Outline
Figures and Tables
Figure 1
View in article
Figure 2
View in article
Figure 3
View in article
Table 1
View in article
Table 2
View in article
REVIEW article
Front. Cardiovasc. Med.
, 22 August 2024
Sec. Cardiovascular Metabolism
Volume 11 - 2024 |
Protein tyrosine phosphatase 1B in metabolic and cardiovascular diseases: from mechanisms to therapeutics
Yan Sun
Frank A. Dinenno
Peiyang Tang
Maria I. Kontaridis
1,2,3
1.
Department of Biomedical Research and Translational Medicine, Masonic Medical Research Institute, Utica, NY, United States
2.
Department of Medicine, Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, United States
3.
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, United States
Article metrics
View details
Abstract
Protein Tyrosine Phosphatase 1B (PTP1B) has emerged as a significant regulator of metabolic and cardiovascular disease. It is a non-transmembrane protein tyrosine phosphatase that negatively regulates multiple signaling pathways integral to the regulation of growth, survival, and differentiation of cells, including leptin and insulin signaling, which are critical for development of obesity, insulin resistance, type 2 diabetes, and cardiovascular disease. Given PTP1B's central role in glucose homeostasis, energy balance, and vascular function, targeted inhibition of PTP1B represents a promising strategy for treating these diseases. However, challenges, such as off-target effects, necessitate a focus on tissue-specific approaches, to maximize therapeutic benefits while minimizing adverse outcomes. In this review, we discuss molecular mechanisms by which PTP1B influences metabolic and cardiovascular functions, summarize the latest research on tissue-specific roles of PTP1B, and discuss the potential for PTP1B inhibitors as future therapeutic agents.
Introduction
Obesity has reached epidemic proportions worldwide, with over 70% of the US population classified as overweight, obese, or morbidly obese. Projections from the World Health Organization indicate that by 2030, half of the US population will be considered obese, with children being the most vulnerable demographic (
). Obesity significantly increases the risk of developing several diseases, including certain cancers, type 2 diabetes (T2D), and cardiovascular disease (CVD) (
). Obesity adversely affects glucose and lipid levels, raises arterial blood pressure, induces inflammation, and impairs pulmonary function, which can lead to cardiac hypertrophy, atrial fibrillation, and heart failure if untreated (
). Despite understanding the contributing factors, the molecular mechanisms linking obesity to CVD remain poorly understood.
Primarily driven by high-calorie diets, sedentary lifestyles, and stress, insulin resistance is linked to the development of T2D, metabolic syndrome and chronic low-grade inflammation (
). Indeed, the global prevalence of T2D, which accounts for 90%–95% of all diabetic cases, has surged by approximately 90% from 1990 to 2021 and is expected to increase an additional 60% by 2050 to affect more than 1.31 billion people (
10
). This rapid rise in T2D, characterized by the dysregulation of glucose homeostasis, poses significant challenges for global health systems.
Insulin resistance is also a primary risk factor for CVD, non-alcoholic fatty liver disease (NAFLD), and hypertension (
11
12
). CVD accounted for 18 million deaths in 2019 and is projected to exceed 22 million by the year 2030 (
13
). Atherosclerosis, characterized by lipid plaque accumulation in arterial walls, underlies most of these cardiovascular events, causing myocardial infarctions (MIs) and strokes (
14
). Chronic low-grade inflammation also plays a crucial role in the pathogenesis of CVD and can exacerbate systemic insulin resistance (
15
).
The interconnection between obesity, insulin resistance, and CVD underscores the need for comprehensive prevention and management strategies, including lifestyle changes and targeted interventions to enhance metabolic and cardiovascular health. In this regard, enzymes that modulate protein signaling pathways are crucial to maintaining cellular homeostasis; their controlled function is instrumental to preventing the development of insulin resistance, T2D, and CVD.
Protein Tyrosine Phosphatase 1B (PTP1B), encoded by the
PTPN1
gene, is a non-receptor protein tyrosine phosphatase (PTP) that has been extensively studied due to its regulatory function in insulin and leptin signaling (
16
17
). As such, PTP1B plays a critical role in metabolic regulation, making it a potential target for therapeutic intervention in obesity and diabetes, as well as in CVD pathophysiology. Here, in this review, we will discuss the significance of the biochemical, functional, and mechanistic roles for PTP1B, and how its hyperactivation can lead to the development of metabolic dysfunction and CVD. We will also discuss the current and emerging therapeutic strategies for treating obesity and diabetes, including use of PTP1B inhibitors.
PTP1B structure and function
PTP1B is a 50kDA protein initially discovered by biochemical purification methods targeting enzymes involved in protein tyrosine dephosphorylation (
16
18
19
). The C-terminus of the enzyme contains two proline-rich domains that interact with Src-homology 3 (SH3) domain-containing proteins to recruit binding substrates (
19
), as well as a hydrophobic domain that anchors to the endoplasmic reticulum (ER) to allow access to intracellular targets (
20
21
). The N-terminal domain of PTP1B houses the catalytic domain, which includes the essential cysteine (Cys215) and arginine (Arg221) residues of the phosphatase signature motif [I/V]HCXXGXXR[S/T], a sequence that defines all protein tyrosine phosphatases (
17
).
The crystal structure of PTP1B has also revealed its biochemical function; it is a PTP that forms a catalytic pocket with high specificity for phosphotyrosine-containing substrates (
22
). Upon substrate binding, PTP1B undergoes a conformation change, closing its WPD loop around the phosphotyrosine residue to stabilize and ready the invariant aspartic acid (Asp181) for hydrolytic catalysis, a process that proceeds in two steps (
23
). First, a nucleophilic attack by the cysteine residue forms a phosphocysteine intermediate, which is hydrolyzed by glutamine (Gln262) and Asp181 (
23
). Next, the closed WPD loop sequesters the phosphocysteine intermediate to prevent the transfer of phosphate to extraneous acceptors. This process is critical to PTP1B's function, making it an integral regulator of signaling pathways involved in metabolic regulation.
PTP1B and RTK signaling
As a PTP, PTP1B catalyzes the dephosphorylation of receptor tyrosine kinases (RTKs) to modulate multiple spatiotemporally complex signaling processes, including those mediated by epidermal growth factor (EGF), leptin, and insulin (
17
). RTKs are single-span transmembrane receptors that facilitate communication between cells and their extracellular environment. Tyrosine phosphorylation (pTyr), a crucial post-translational modification, regulates essential biological processes that include cellular proliferation, migration, and invasion (
24
). The process is mediated by the coordinated actions of both protein tyrosine kinases (PTKs), which add phosphate (PO
) groups, and PTPs, which remove these phosphate groups (
25
26
). Disruption of this delicate balance between PTKs and PTPs can result in aberrant pTyr. While most previous research historically focused on the role of PTKs, recent studies have emphasized the critical functions of PTPs in maintaining this balance. As PTPs can act as both initiators and terminators of pTyr signaling, their importance in maintaining cellular homeostasis is paramount (
27
28
); absence or dysfunction of PTPs can lead to a myriad of pathological conditions, including autoimmunity, cancer, CVD, and obesity-related metabolic disorders (
29
30
).
Insulin signaling and the role of PTP1B
In healthy individuals, food intake elevates blood glucose and stimulates insulin release from the pancreas, inducing a feedback mechanism that increases glucose uptake by peripheral tissues to regain normal blood glucose concentrations (
31
32
). Insulin resistance occurs when tissues such as skeletal muscle, adipose tissue, and the liver become less responsive to insulin, leading to reduced glucose uptake, hyperglycemia, and hyperinsulinemia, and eventually, T2D (
33
34
).
Insulin signaling, a key RTK pathway, and PTP1B regulation are integral mediators of this biological process. Briefly, when insulin is released into the bloodstream by the pancreas, it binds to cells through the insulin receptor (IR), inducing autophosphorylation and activation of its intrinsic kinase activity (
35
). The activated receptor then phosphorylates its downstream effectors, the insulin receptor substrates (IRS1/2), which mediate activation of phosphatidylinositol (PI) 3′-kinase (PI3K), a lipid kinase complex consisting of a regulatory p85 subunit and a catalytic p110 subunit that phosphorylates the 3′-hydroxyl group of phosphoinositides. Specifically, with respect to insulin signaling, phosphorylated IRS proteins interact with the regulatory p85 subunit of PI3K through their SH2 domains, inducing a conformational change that relieves the inhibition on the p110 catalytic subunit, recruiting the now activated PI3K complex from the cytosol to the plasma membrane (PM). Once at the membrane, PI3K can phosphorylate its substrate, phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2, also known as PIP2] to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3), driving downstream signaling and activation of protein kinase B (PKB; also known as AKT) (
36
). AKT then further promotes activation of downstream effectors involved in protein synthesis and survival, as well as induces translocation of glucose transporters to the cell membrane, resulting in increased glucose uptake by the cells (
37
) (
Figure 1
).
Figure 1
PTP1B negatively regulates this process by directly dephosphorylating both the IR and its downstream effectors, IRS1 and IRS2, reducing their activity and downregulating PI3K/AKT signaling (
38
). Indeed, whole-body PTP1B knockout (KO) mice exhibit enhanced insulin sensitivity, elevated phosphorylation of IR and IRS-1, and resistance to high-fat diet (HFD)-induced weight gain and obesity (
27
). Functionally, PTP1B KO mice have elevated basal metabolic rates and increased energy expenditures (
39
). Interestingly, the effects of reduced adiposity are not consequent to decreased fat cell numbers; rather, they are mediated by having decreased fat cell sizes (
39
). Collectively, these findings demonstrate a critical role for PTP1B in the regulation of metabolism
in vivo
PTP1B regulation of leptin signaling
Leptin, an adipocyte-secreted hormone, acts in the mediobasal hypothalamic nuclei to suppress food intake and increase energy expenditure, regulating energy balance and body mass (
40
). As such, circulating leptin levels correlate with adiposity (
41
). Mechanistically, leptin binds to the leptin (LR), a type I cytokine receptor that is expressed in the hypothalamus, and activates its effector JAK2, a protein that promotes the growth and division of cells (
42
). Once activated, JAK2 induces activation of the IRS proteins, which like insulin signaling, can lead to the activation of the PI3K/AKT pathway (
43
) (
Figure 2
). Activation of JAK2 also directly phosphorylates the LR itself, allowing for recruitment of the SH2 domain-containing protein-tyrosine phosphatase 2 (SHP2), another critical PTP that promotes activation of the extracellular signal-regulated kinase 1/2 (ERK1/2)-mitogen activated protein kinases (MAPK) pathway, which is critical for the proliferation and growth of cells (
44
45
). In parallel, JAK2-mediated LR phosphorylation also drives activation of the signal transducer and activator of transcription factor 3 (STAT3) pathway, which suppresses transcription of both the hypothalamic neuropeptide Y (Npy) and agouti-related protein (Agrp), co-expressive neuropeptides that stimulate food intake and repress energy expenditure (
46
).
Figure 2
Like with insulin, PTP1B is a negative regulator of leptin signaling by directly dephosphorylating JAK2, thereby blocking the phosphorylation and activities of both the receptor and STAT3 (
47
). PTP1B KO mice have increased leptin sensitivity, lower leptin/body fat ratios, and enhanced hypothalamic signaling, leading to reduced adiposity and increased energy expenditure (
48
).
Effects of PTP1B in metabolism
Located on chromosome 20q13.1-13.2, several single nucleotide polymorphisms (SNPs) in the
PTPN1
gene have been linked to obesity and diabetes in various populations. In French Canadians, for example, at least six PTP1B SNPs have been associated with these conditions (
49
50
). PTP1B SNPs have also been identified in individuals with early onset diabetes in Danes, Canadians, and Italians (
10
51
52
). Moreover, the PTP1B SNP rs3787348 is linked to a poorer weight reduction outcome in obese Japanese patients (
53
). Based on this, and the PTP1B global KO mouse data, it is clear that PTP1B influences glucose homeostasis and energy balance through its actions on insulin and leptin pathways. Inhibition of PTP1B enhances signaling to these pathways, improving glucose uptake and energy expenditure, and thus highlights the crucial role for PTP1B in metabolic health.
However, despite these overall positive outcomes, global, as well as myeloid-specific, PTP1B KO mice can develop acute myeloid leukemia and have been shown to have reduced lifespans (
27
54
), suggesting differential tissue-specific effects of PTP1B. As such, global therapeutic targeting of PTP1B, particularly for treatment of metabolic diseases, appears to be rather complicated. To therefore circumvent this issue and to better elucidate the precise molecular, functional, and biological regulations of PTP1B, tissue-specific deletion models for PTP1B have been generated and studied (
Table 1
).
Table 1
Site of deletion
Genotype
Observed phenotype
References
Global
PTP1B
−/−
1.
Lower blood glucose concentrations
2.
Enhanced insulin sensitivity
3.
Increased basal metabolic rate and total energy expenditure
4.
Resistant to weight gain and remained insulin sensitive on HFD
27
55
Muscle
PTP1B
−/−
1.
Increased muscle glucose uptake
2.
Improved systemic insulin sensitivity
3.
Enhanced glucose tolerance
56
57
Adipocyte
PTP1B
−/−
1.
No differences in body weight/adiposity compared to PTP1B
+/+
2.
Increased adipocyte size
3.
Increased circulating glucose and leptin levels
4.
Reduced leptin sensitivity
5.
Increased basal lipogenesis
58
59
Neuronal
PTP1B
−/−
1.
Reduced weight and adiposity
2.
Increased energy expenditure
3.
Hypersensitive to leptin and elevated leptin levels
4.
Improved glucose homeostasis
57
60
POMC
PTP1B
−/−
1.
Reduced adiposity
2.
Improved leptin sensitivity
3.
Increased energy expenditure
4.
Reduced BP response to ganglionic blockade
5.
Increased vascular adrenergic reactivity
6.
Exhibited a blunted increased in diastolic and mean BP
61
Myeloid
PTP1B
−/−
1.
Impaired BMDC activation
2.
Decreased migratory capacity of epidermal DC
3.
Fail to present antigen to T cells as efficiently as control BMDC
4.
Shortened lifespan and development of acute leukemia
54
Liver
PTP1B
−/−
1.
Improved glucose homeostasis and lipid profiles
2.
Increased hepatic insulin signaling
3.
Decreased triglyceride and cholesterol levels
4.
Protective effect against endoplasmic reticulum stress
62
63
Endothelial cell
PTP1B
−/−
1.
Promotes cardiac and extracardiac angiogenesis during chronic pressure overload-induced hypertrophy
2.
Reduce hypoxia, oxidative stress and fibrosis
3.
Enhanced cardiac VEGF signaling and increased Caveolin-1 expression
4.
Restore altered NO production in the peripheral circulation in CHF
64
66
Islet
PTP1B
−/−
1.
Absence of islet PTP1B increased graft functional vascularization by increasing the number of newly formed vessels
2.
Up-regulation of several EC markers and reduced IEC loss in culture
3.
Enhanced VEGF-A production and activation of the PGC1α/ERRα axis
67
Effects of global and tissue specific deletion of PTP1B in rodents.
HFD, high fat diet; BP, blood pressure; POMC, pro-opiomelanocortin; BMDC, bone marrow dendric cells; DC, dendric cell; VEGF, vascular endothelial growth factor; NO, nitric oxide; CHF, chronic heart failure; EC, endothelial cell; IEC, induced endothelial cell.
Skeletal muscle
PTP1B deletion in skeletal muscle cells enhances systemic insulin sensitivity and increases glucose uptake in the muscle, independent of body weight and adiposity (
56
). These mice also exhibit increased insulin signaling, as indicated by enhanced phosphorylation of the IR and its downstream effector IRS1, as compared to controls (
56
). PI3K activity and phosphorylation of both AKT and ERK1/2 are also elevated in these mice. Despite these effects, however, deficiency of PTP1B in skeletal muscle does not affect lipid profiles, leptin levels, leptin sensitivity, body weight, or adiposity (
56
68
), suggesting that these mechanisms for PTP1B regulation reside in other tissues and/or cell types.
Adipose
Adipose-specific PTP1B KO mice maintain similar body weight to controls when fed a HFD, but have larger adipocytes, increased circulating leptin levels, and increased basal lipogenesis (
58
). These mice have decreased phosphorylation of IR and its downstream effector AKT and have overall increased expression of lipogenic genes (
58
). Moreover, pyruvate kinase M2 (PKM2) is a newly identified substrate for PTP1B in adipocytes, but its mechanism of regulation in these cells remains unclear (
69
). In addition, PTP1B's role in different adipose depots is variable, influencing adipogenesis and insulin sensitivity differently between white and brown adipocytes; specifically, PTP1B knockdown in 3T3-L1 adipocytes inhibits adipogenesis (
69
), whereas PTP1B deficiency in brown adipocytes accelerates adipogenesis and enhances insulin sensitivity through activation of AKT and increased resistance to TNF
-induced apoptosis (
70
71
).
Liver
Mice with liver-specific PTP1B deletion show increased insulin sensitivity and suppressed hepatic gluconeogenesis and lipogenic genes, without affecting weight gain (
62
63
). In addition, these mice have alleviated endoplasmic reticulum (ER) stress following HFD, with decreased phosphorylation of downstream p38-MAPK and c-Jun N-terminal kinase (JNK)-MAPK signaling pathways, as well as reduced ER-resident proteins, PERK and eukaryotic initiation factor 2 α (eIF2α) factors (
62
63
). This decreased signaling also leads to lowered expression of stress-related transcription factors and improved lipid profiles (
62
63
). Liver-specific PTP1B KO, however, does not impact leptin levels, leptin sensitivity, body weight, or adiposity (
62
63
), underscoring the liver-specific benefits of PTP1B inhibition in metabolic regulation.
Neuronal
Neuronal deletion of PTP1B in mice show decreased body mass and adiposity, as well as improved glucose homeostasis (
57
). These mice also exhibit increased physical activity and energy expenditure and are hypersensitive to leptin with elevated leptin levels (
57
). Moreover, deletion of PTP1B in arcuate pro-opiomelanocortin (POMC), a specific regulatory neuronal subpopulation that controls metabolism and is expressed only in hypothalamus and regions of the spinal cord and brain stem, reduces adiposity, improves leptin sensitivity, and increases energy expenditure (
61
72
). These mice are also protected against leptin- and sympathetically mediated increases in blood pressure. Collectively, these data suggest that PTP1B modulates leptin production and resistance primarily through activation of pathways within the central nervous system (CNS) (
61
). In addition, POMCs induce brain-derived neurotrophic factor (BDNF) signaling in the hypothalamus, mediating neural connectivity and neurite outgrowth (
73
). In this regard, PTP1B modulates this process by acting as a direct negative regulator of the downstream BDNF effector, tropomyosin receptor kinase B (TrkB) (
60
73
74
), thus increasing both AKT and ERK activation. These effects highlight the critical role of the CNS in PTP1B-mediated metabolic regulation and the control of food intake and energy expenditure.
PTP1B in CVDs
As previously discussed, obesity is a major risk factor for CVD, increasing mortality and morbidity, particularly in individuals with central adiposity (
75
). Obesity is also associated with the development of high blood pressure, a leading risk factor for stroke, cardiac hypertrophy, and heart failure (
76
77
). Several studies have established a significant link between PTPs, PTKs and cardiac pathophysiology (
78
). Indeed, increased activation of PTP1B in the heart is associated with development of heart failure in both rats and humans (
78
79
). Cardiac contractile dysfunction and intracellular calcium dysregulation are also linked to elevated levels of PTP1B (
80
). Thus, there is precedence for a critical role for PTP1B in CVD (
81
).
PTP1B and endothelial cells (ECs)
Endothelial dysfunction is a primary event in the progression of CVD and is a known predictor of diabetes- and obesity-related CVD (
82
). Increased PTP1B expression in ECs impairs macro- and micro-vascular systems and increases the risk of having an MI or ischemic stroke (
64
83
87
). Mechanistically, enhanced PTP1B-mediated signaling in ECs inhibits activation of AKT and blocks endothelial nitric oxide synthase (eNOS), an enzyme responsible for producing nitric oxide (NO), a potent vasodilator and regulator of glucose uptake (
64
88
). Inhibition of PTP1B enhances serine phosphorylation of eNOS and improves NO-mediated vasodilation in mice with chronic heart failure induced by coronary ligation (
64
). These data suggest that PTP1B inhibition could potentially be considered for patients with CVD and/or endothelial dysfunction.
Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) and its ligand VEGF-A are key mediators of angiogenesis, the process by which existing blood vessels grow (
89
). Binding of VEGF-A to VEGFR2 induces autophosphorylation of the receptor and, subsequently, leads to activation of multiple crucial downstream signaling pathways necessary for survival, proliferation, and migration of ECs (
90
). To drive angiogenesis, VEGFR signaling activates Src, which induces phosphorylation of VE-Cadherin, as well as P38-MAPK, to mediate EC migration (
91
). In addition, VEGFR activation induces signaling to both ERK1/2 and PI3K/AKT, to promote EC proliferation and EC survival, respectively (
92
) (
Figure 3
).
Figure 3
Here too, PTP1B has a prominent role in CVD; it directly dephosphorylates VEGFR2 to inhibit angiogenesis (
66
). Mice with endothelial-specific deletion of PTP1B, however, have improved angiogenesis, enhanced wound healing, and are protected against development of chronic heart failure post-MI (
66
93
). Primary ECs isolated from these mice reveal that the mechanism of this regulation is mediated by enhanced VEGF-A-induced VEGFR2 activity, which leads to increased ERK signaling to induce angiogenesis (
66
). Similar effects on angiogenesis, revascularization and survival are also noted in PTP1B-deleted pancreatic islets (
67
), as well as in human umbilical vein ECs, both
in vitro
and
in vivo
94
).
PTP1B and vascular smooth muscle cells (VSMCs)
The motility and proliferation of VSMCs is critical for neointima formation and remodeling in response to vascular injury (
95
). Elevated levels of platelet-derived growth factor (PDGF) and/or fibroblast growth factor-2 (FGF2) contribute to this remodeling event, mediating autophosphorylation and activation of PDGF receptor β (PDGF-βR) and increased downstream signaling (
96
). Here, induction of NO can increase PTP1B activity, whose direct binding to the PDGF-βR can then inhibit downstream signaling and suppress proliferation and motility in cultured SMCs (
96
98
).
Indeed, adenoviral overexpression of PTP1B blocks insulin-mediated activation of IR and decreases cell motility, whereas dominant-negative expression of PTP1B attenuates NO-mediated inhibition of cell motility (
98
). Treatment of injured arteries with dominant negative PTP1B adenovirus, however, increases cell proliferation, intimal cell number, and neointima formation, without affecting apoptosis. Moreover, primary isolated newborn rat aortic SMCs treated with an antisense oligonucleotide against PTP1B enhances cell motility and increases pTyr of several adhesion molecules, including p130
cas
, paxillin and focal adhesion kinase (FAK) (
99
) (
Figure 3
). Together, these findings demonstrate that PTP1B is an important regulatory protein involved in motility and proliferation, and that it may be a good potential therapeutic target for treating VSMC pathophysiology.
PTP1B and cardiac myocytes
Cardiomyocytes (CMs) are contractile muscle cells that allow the heart to maintain proper pumping function (
100
). CMs are also the major source of VEGF signaling in the heart (
101
102
). Here, activation of P38-MAPK promotes secretion of VEGF-A, which in turns acts as a feedback mechanism to stimulate binding and activation of the VEGFR (
103
). CM-mediated VEGF signaling also mediates cardiac morphogenesis, transforming cardiac ECs into mesenchymal cells in mice (
104
105
). However, the mechanisms for how PTP1B is involved in this process in CMs requires further study.
Interestingly, research on PTP1B activity in CMs has demonstrated both protective and deleterious effects. For example, PTP1B directly binds PKM2, increasing its activity in CMs (
106
). Since PKM2 is a key cell cycle regulator, increasing its activity induces CM cell division, improves cardiac function, and extends long-term survival after acute or chronic MI (
107
) (
Figure 3
). Conversely, PTP1B overexpression mediates age-induced CM contractile dysfunction and other myocardial anomalies (
80
108
).
In response to HFD, global deletion of PTP1B in mice reduces cardiac pathologies, including hypertrophy (
108
). Our own laboratory also recently demonstrated that CM-specific deletion of PTP1B in mice ameliorates HFD-induced cardiomyopathy and cardiac steatosis (
106
). Furthermore, metabolomics data revealed that CM-specific deletion of PTP1B elevates fatty acid oxidation and lipolysis, but reduces glucose metabolism (
106
). In response to hypoxia-reoxygenation of isolated primary neonatal mouse CMs, PTP1B expression increases; ablation of PTP1B in these cells increases AKT activity and decreases hypoxia-associated apoptosis (
109
). These findings indicate that PTP1B inhibition may mitigate cardiac abnormalities and improve heart function.
While these data all suggest a protective role for PTP1B deletion in the heart, Coulis et al. have found that CM-specific deletion of PTP1B in mice may also be pathological, inducing a hypertrophic phenotype that is exacerbated by pressure overload (
110
). Specifically, they found that argonaute 2 (AGO2), a critical component of the RNA-induced silencing complex, is inactivated in response to CM-specific deletion of PTP1B, thereby preventing miR-208b-mediated inhibition of mediator complex subunit 13 (MED13) and leads to thyroid hormone-associated pathological cardiac hypertrophy (
110
). However, in this regard, inhibition of miR-208b has previously been shown to improve, not induce, cardiac dysfunction in titin-induced dilated cardiomyopathy (
111
). Moreover, upregulation of MED13 is protective in the heart, conferring resistance to obesity (
112
). Regardless, it remains possible that different pathological stimuli may lead to different outcomes and/or that too much or too little PTP1B can lead to similar, but distinct, pathological outcomes (
106
). Exactly if and how PTP1B is involved in modulating these various physiological vs. pathological responses in the heart remains to be determined (
106
).
PTP1B as a potential therapeutic target
Overall, given PTP1B's critical role in insulin and leptin signaling, it is considered an excellent target for treating obesity and diabetes (
17
). However, targeting PTP1B, in a cellular and tissue-specific manner, has been challenging, particularly because of its positively charged active site, its selectivity, and its bioavailability (
78
113
). Consequently, only a few PTP1B inhibitors have been tested in clinical trials, and most have, unfortunately, been discontinued due to insufficient efficiency, lack of specificity and detrimental side effects (
114
116
) (
Table 2
). Therefore, more research is needed to fully elucidate the effects of PTP1B inhibition in cardiometabolic diseases.
Table 2
PTP1B inhibitor
Inhibitor type
In diabetic & cardiovascular studies
IC50 value
References
MSI-1436/trodusquemine
Noncompetitive, reversible, allosteric inhibitor
1.
Reduced fat & insulin levels in HFD induced obese mice
2.
Weight loss, suppressed food intake, decreased adipocyte size/lipid content & lowered plasma insulin levels
3.
Reduced osteogenic & myofibrogenic VIC differentiation
4.
Decreased VIC osteogenic differentiation, inhibits myofibroblast, & protective against aortic valve stenosis
5.
Decreased phosphorylation of p44/42 MAP kinase in breast cancer model mice
0.6 μM–40.6 μM, depending on PTP1B enzyme form
117
118
ISIS 113715
Antisense inhibitor
1.
Inhibited PTP1B mRNA and protein expression in monkey hepatocytes
2.
Reduced PTP1B mRNA expression in liver/adipose tissues in monkeys
3.
Increased adiponectin concentrations & lowered insulin responses in monkeys
4.
Improved insulin sensitivity & normalized plasma glucose levels in mice and monkeys
5.
Downregulated lipogenic genes within fat and liver as well as adipocyte differentiation associated genes in fat tissue of mice
6.
Tolerated and safe in people, improved dyslipidemia & increased adiponectin, decreased body weight
<0.01 μM
59
119
121
BDB
Competitive, selective inhibitor
1.
Antidiabetic effects in spontaneously developing diabetic mice.
2.
Marked improvements in pancreatic islet cell architecture and increased ratios of β-cells to α-cells
1.86 μM
87
DPM-1001
Analog of MSI-1436
1.
Reversed obesity
2.
Improved glucose tolerance
3.
Insulin sensitivity
0.1 μM
122
Isoxazol-5 (4H) one derivative C3
Competitive, binds to the active site
1. Suppressed weight gain in mice upon HFD
2.3 µM
123
TCS 401
Competitive, selective inhibitor
1.
Increased dopamine response to insulin & general responsiveness to insulin compared to the HFD control mice
2.
Increased ERK & AKT expression in RPE & CMECs
3.
Decreased apoptosis & caspase 3 activity in CMEC
2 μM
124
127
XWJ24
Competitive and selective inhibitor, 4.5 times more potent than TC-PTP
No studies in the context of obesity, diabetes or cardiovascular disease
0.6 μM
128
An overview of PTP1B inhibitors.
HFD, high fat diet; VIC, valvular interstitial cells; RPE, retinal pigment epithelial; CMEC, cardiac microvascular endothelial cell.
Ertiprotafib, a monocarboxylic acid mimetic, is a noncompetitive multiple-action inhibitor (
129
). It was the first PTP1B inhibitor to be tested in clinical trials for the treatment of diabetes (
130
). This inhibitor has an atypical mechanism of action; while most small molecules bind to and increase their target's melting temperature (Tm) to stabilize their interaction, ertiprotafib lowers the Tm of PTP1B, destabilizing it (
131
132
). Indeed, the mechanism by which ertiprotafib inhibits PTP1B activity is mediated by inducing protein aggregation (
133
). However, the selectivity of this compound is very low, with IC50 values of 1.6–29 µM, depending on assay conditions (
129
). Therefore, development of newer and more specific inhibitors was needed.
Trodusquemine, also known as MSI-1436, is a natural aminosterol cholestane that is a noncompetitive, reversible, and allosteric inhibitor of PTP1B (
117
134
). In terms of specificity, this small molecule targets a novel allosteric binding site located within the C-terminus of PTP1B, allowing it to bind with affinity values that range from 0.6 μM to 40 6 μM, depending on the enzyme form (
117
). Because of its high specificity, trodusquemine was initially considered to be the more effective inhibitor with fewer off-target side effects (
135
). Indeed, in HFD-fed mice, MSI-1436 significantly decreased obesity by reducing insulin levels, decreasing body weight, lowering lipid content, decreasing adipocyte size, and suppressing food intake (
118
). In addition, MSI-1436 reduced osteogenic and myofibrogenic valvular interstitial cell (VIC) differentiation, alleviating aortic valve fibro-calcification and stenosis in a diet-induced mouse model of calcific aortic valve disease (
136
). Unfortunately, though effective in these mouse studies, this inhibitor was discontinued for use in human clinical trials due to its low activity and poor bioavailability in patients (
19
).
JTT-551, a mixed-type PTP1B inhibitor, was shown to have good selectivity. Like trodusquemine, chronic administration of JTT-551 in mice with diet-induced obesity demonstrated anti-obesity properties (
137
). In addition, JTT-551 reduced blood glucose and exhibited antidiabetic effects, without changes in body weight, in diabetic mice (
137
). Taken together, these data indicated that JTT-551 was an effective inhibitor for treatment of T2D and obesity; however, trials here too were discontinued due to insufficient efficacy and increased adverse effects in patients (
138
).
New therapies on the horizon for PTP1B inhibition
Fortunately, several new PTP1B inhibitors have been recently generated and are in process of being tested for efficacy against a myriad of cardiometabolic diseases, including T2D. The hope is that one (or several) will succeed in patient trials and provide future therapeutic benefits for these devastating diseases.
IONIS-PTP-1BRx, also known as ISIS-113715, is an antisense PTP1B inhibitor with an IC50 of less than 0.01 μM (
59
). In obese insulin-resistant monkeys, this inhibitor improved insulin sensitivity, increased adiponectin concentration, and lowered insulin responses (
59
). Similarly, in insulin-resistant diabetic mice, IONIS-PTP-1BRx improved insulin sensitivity, normalized plasma glucose levels, and decreased expression of lipogenic genes in both fat and liver, downregulating adipocyte differentiation (
120
). In 2018, IONIS-PTP-1BRx made its way to clinical trials, and preliminary data indicate that treated T2D diabetic patients have reduced body weight and decreased mean HbA1c levels (
121
), all without adverse interactions with other antidiabetic drugs (
119
). However, as of the date of this submission, no further updates have been posted about this study.
BDB [3-bromo-4,5-bis(2,3-dibromo-4,5-dihydroxybenzyl)-1,2-benzenediol] is a recently developed competitive inhibitor of PTP1B with demonstrated high selectivity (
87
).
In vitro
, BDB is cell-permeable and enhances insulin signaling. Moreover, oral administration of BDB leads to antidiabetic effects in spontaneously developing diabetic mice, with marked improvements in pancreatic islet cell architecture and increases in ratios of β-cells to α-cells (
87
). No information, however, is yet available about its progression to clinical trials.
DPM-1001, an analog of MSI-1436 with an IC50 of 0.1 μM, reverses obesity and improves insulin sensitivity and glucose tolerance in HFD mice (
139
). In May of 2022, DepYmed released a statement that it received FDA orphan drug designation for the clinical candidate DPM-1001, for the treatment of Wilson Disease, a rare genetic disorder that prevents the body from removing copper, causing the metal to build up in the liver, brain, and corneas (
122
) (
). This classification for DPM-1001 is an important milestone, as it furthers the development and progression of PTP1B inhibitors for use in diseased patients.
Other potent inhibitors have also been recently studied in the context of metabolism. A competitive derivative of Isoxazol-5(4H) suppresses weight gain in HFD mice, although at a comparatively reduced potency than other PTP1B inhibitors (
123
). TCS 401, another competitive and selective inhibitor, increases dopamine responses to insulin in HFD mice (
124
). Inhibitors, such as XWJ24 and compounds from D. crassirhizomai and M. alba, have recently shown strong PTP1B inhibition, but have yet to be tested in HFD or CVD studies (
128
140
141
). Finally, a new patent application has identified 5-(naphthalen-2-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives (represented by “formula 1”) as a newly garnered PTP1B inhibitor, but its efficacy and specificity have yet to be determined (
114
).
Navigating the challenges: future opportunities for PTP1B inhibitors in disease treatment
New targeting strategies for PTP1B inhibition
The transcriptional and translational regulation of PTP1B is well studied, providing potential novel sites for therapeutic targeting, particularly for metabolic disorders and cancers. In this regard, characterization of the PTP1B promoter region revealed several binding sites for transcription factors such as Egr-1, Sp1, Sp3 (
142
), YB-1 (
143
), NF-κB (
144
) and HIF (
145
). These factors can be activated by various stimuli, including glucose, insulin, proinflammatory cytokines, and oncoproteins (
146
). Additionally, PTP1B expression is regulated by several miRNAs, including miR-338-3p, miR-744, miR-122, miR-193a-3p, miR-135a, miR-146-b, and miR-206 (
147
152
). Each of these can be considered as additional, indirect PTP1B inhibitors for future studies, as they have the potential to be targeted with high specificity, to reduce downstream PTP1B signaling, and hopefully, to prevent development of insulin resistance, T2D, CVD, as well as onset of other diseases such as cancer. The efficacy of this strategy remains to be determined.
Outside the box approaches for PTP1B inhibition
Over the past few decades, numerous PTP1B inhibitors have been identified, but their lack of specificity and cellular permeability pose significant challenges for clinical use (
115
). Most inhibitors target the catalytic active site, leading to non-specific inhibition of all PTPs (
153
). Despite efforts to develop more specific inhibitors, the high conservation of the catalytic site among PTPs, particularly TCPTP, remains a major obstacle. To overcome these challenges, researchers are exploring innovative strategies including high-throughput screening (
154
), virtual screening (
155
), DNA-encoded libraries (
156
), and PROTAC approaches (
157
) to develop drugs with greater efficacy and increased specificity. Additionally, designing inhibitors with improved membrane permeability and bioavailability is crucial. In this regard, nanoparticle-based delivery systems and graphene quantum dots show promise in enhancing oral bioavailability and specificity (
158
159
). Addressing these challenges will be necessary for developing effective and safe PTP1B inhibitors for clinical treatment of various diseases in the near future.
Summary
PTP1B signaling is a critical regulator of glucose homeostasis and energy balance, conducive to mediating the onset of obesity, insulin resistance, T2D, and CVD (
49
160
). Consequently, inhibition of PTP1B is an attractive novel strategy for treating these diseases. Though significant progress has been made in understanding the molecular mechanisms of PTP1B regulation in metabolic processes that affect diabetes, obesity and the heart, tissue-specific targeting and selective potency with existing PTP1B inhibitors remains challenging. Future research is promising in this regard, and advancements in this field, through novel and targeted modulation of PTP1B, are likely to yield effective results and therapies for treatment of individuals with these devastating ailments.
Statements
Author contributions
YS: Funding acquisition, Investigation, Methodology, Validation, Writing – original draft. FD: Investigation, Methodology, Supervision, Validation, Writing – review & editing. PT: Investigation, Visualization, Writing – original draft. MIK: Conceptualization, Funding acquisition, Investigation, Project administration, Resources, Supervision, Validation, Writing – original draft, Writing – review & editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article.
This work was supported by the National Institutes of Health (Grants R01-HL122238, R01-HL102368), the American Heart Association Transformation Grant Awards (20TPA35490426, 23TPA1065811), and the Masonic Medical Research Institute to MIK.; and the Halfond Weil Postdoctoral Fellowship to YS.
Acknowledgments
Figures were created using
BioRender.com
. The manuscript writing was edited and grammatically checked and cross-referenced using Chegg and ChatGPT.
Conflict of interest
MIK has received grant funding from Onconova Therapeutics and is a consultant for BioMarin Pharmaceutical Inc; both funding and consulting projects are independent of the work in this manuscript and have no overlap with the submitted work.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
Ward
ZJ
Bleich
SN
Cradock
AL
Barrett
JL
Giles
CM
Flax
et al
Projected U.S. State-level prevalence of adult obesity and severe obesity
N Engl J Med
2019
381
2440
50
10.1056/NEJMsa1909301
Pubmed Abstract
CrossRef
Google Scholar
2.
Chawla
Chawla
Jaggi
Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum?
Indian J Endocrinol Metab
. (
2016
20
546
51
10.4103/2230-8210.183480
Pubmed Abstract
CrossRef
Google Scholar
3.
Lavie Carl
Mcauley Paul
Church Timothy
Milani Richard
Blair Steven
Obesity and cardiovascular diseases
J Am Coll Cardiol
. (
2014
63
1345
54
10.1016/j.jacc.2014.01.022
Pubmed Abstract
CrossRef
Google Scholar
4.
Lavie
CJ
Alpert
MA
Arena
Mehra
MR
Milani
RV
Ventura
HO
Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure
JACC Heart Fail
. (
2013
93
102
10.1016/j.jchf.2013.01.006
Pubmed Abstract
CrossRef
Google Scholar
5.
Cersosimo
Defronzo
RA
Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases
Diabetes Metab Res Rev
. (
2006
22
423
36
10.1002/dmrr.634
Pubmed Abstract
CrossRef
Google Scholar
6.
Kolwicz
SC
JR
Purohit
Tian
Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes
Circ Res
. (
2013
113
603
16
10.1161/CIRCRESAHA.113.302095
Pubmed Abstract
CrossRef
Google Scholar
7.
Saklayen
MG
The global epidemic of the metabolic syndrome
Curr Hypertens Rep
2018
20
12
10.1007/s11906-018-0812-z
Pubmed Abstract
CrossRef
Google Scholar
8.
Kosmas
CE
Silverio
Tsomidou
Salcedo
MD
Montan
PD
Guzman
The impact of insulin resistance and chronic kidney disease on inflammation and cardiovascular disease
Clin Med Insights Endocrinol Diabetes
. (
2018
11
1179551418792257
10.1177/1179551418792257
Pubmed Abstract
CrossRef
Google Scholar
9.
Ong
KL
Stafford
LK
Mclaughlin
SA
Boyko
EJ
Vollset
SE
Smith
AE
et al
Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021
Lancet
. (
2023
402
203
34
10.1016/S0140-6736(23)01301-6
Pubmed Abstract
CrossRef
Google Scholar
10.
Echwald
SM
Bach
Vestergaard
Richelsen
Kristensen
Drivsholm
et al
A P387l variant in protein tyrosine phosphatase-1B (PTP-1B) is associated with type 2 diabetes and impaired serine phosphorylation of PTP-1B in vitro
Diabetes
. (
2002
51
10.2337/diabetes.51.1.1
Pubmed Abstract
CrossRef
Google Scholar
11.
Gast
KB
Tjeerdema
Stijnen
Smit
JW
Dekkers
OM
Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis
PLoS One
. (
2012
e52036
10.1371/journal.pone.0052036
Pubmed Abstract
CrossRef
Google Scholar
12.
Mottillo
Filion
KB
Genest
Joseph
Pilote
Poirier
et al
The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis
J Am Coll Cardiol
. (
2010
56
1113
32
10.1016/j.jacc.2010.05.034
Pubmed Abstract
CrossRef
Google Scholar
13.
Nawsherwan
Mubarik
Bin
Le
Sang
Lin
et al
Epidemiological trends in cardiovascular disease mortality attributable to modifiable risk factors and its association with sociodemographic transitions across BRICS-plus countries
Nutrients
2023
15
17
):
3757
10.3390/nu15173757
Pubmed Abstract
CrossRef
Google Scholar
14.
Dutta
Courties
Wei
Leuschner
Gorbatov
Robbins
CS
et al
Myocardial infarction accelerates atherosclerosis
Nature
. (
2012
487
325
10.1038/nature11260
Pubmed Abstract
CrossRef
Google Scholar
15.
Kosmas
CE
Bousvarou
MD
Kostara
CE
Papakonstantinou
EJ
Salamou
Guzman
Insulin resistance and cardiovascular disease
J Int Med Res
. (
2023
51
3000605231164548
10.1177/03000605231164548
Pubmed Abstract
CrossRef
Google Scholar
16.
Tonks
NK
Diltz
CD
Fischer
EH
Characterization of the major protein-tyrosine-phosphatases of human placenta
J Biol Chem
. (
1988
263
6731
10.1016/S0021-9258(18)68703-4
Pubmed Abstract
CrossRef
Google Scholar
17.
Tonks
NK
PTP1B: from the sidelines to the front lines!
FEBS Lett
. (
2003
546
140
10.1016/S0014-5793(03)00603-3
Pubmed Abstract
CrossRef
Google Scholar
18.
Tonks
NK
Diltz
CD
Fischer
EH
Purification of the major protein-tyrosine-phosphatases of human placenta
J Biol Chem
1988
263
6722
30
10.1016/S0021-9258(18)68702-2
Pubmed Abstract
CrossRef
Google Scholar
19.
Liu
Hill
DE
Chernoff
Direct binding of the proline-rich region of protein tyrosine phosphatase 1B to the SRC homology 3 domain of p130(CAS)
J Biol Chem
1996
271
31290
10.1074/jbc.271.49.31290
Pubmed Abstract
CrossRef
Google Scholar
20.
Frangioni
JV
Beahm
PH
Shifrin
Jost
CA
Neel
BG
The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence
Cell
1992
68
545
60
10.1016/0092-8674(92)90190-N
Pubmed Abstract
CrossRef
Google Scholar
21.
Haj
FG
Verveer
PJ
Squire
Neel
BG
Bastiaens
PI
Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum
Science
2002
295
1708
11
10.1126/science.1067566
Pubmed Abstract
CrossRef
Google Scholar
22.
Barford
Flint
AJ
Tonks
NK
Crystal structure of human protein tyrosine phosphatase 1B
Science
. (
1994
263
1397
404
10.1126/science.8128219
Pubmed Abstract
CrossRef
Google Scholar
23.
Pannifer
ADB
Flint
AJ
Tonks
NK
Barford
Visualization of the cysteinyl-phosphate intermediate of a protein-tyrosine phosphatase by x-ray crystallography*
J Biol Chem
. (
1998
273
10454
62
10.1074/jbc.273.17.10454
Pubmed Abstract
CrossRef
Google Scholar
24.
Hunter
The genesis of tyrosine phosphorylation
Cold Spring Harb Perspect Biol
2014
a020644
10.1101/cshperspect.a020644
Pubmed Abstract
CrossRef
Google Scholar
25.
Yip
SC
Saha
Chernoff
PTP1B: a double agent in metabolism and oncogenesis
Trends Biochem Sci
2010
35
442
10.1016/j.tibs.2010.03.004
Pubmed Abstract
CrossRef
Google Scholar
26.
Shenolikar
Chapter 105 - Serine/Threonine phosphatase inhibitor proteins
. In:
Ralph
A. Bradshaw
Edward
, editors.
Handbook of Cell Signaling
2nd ed
San Diego
Academic Press
2023
). p.
627
29
10.1016/B978-012124546-7/50466-6
CrossRef
Google Scholar
27.
Elchebly
Payette
Michaliszyn
Cromlish
Collins
Loy
AL
et al
Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene
Science
. (
1999
283
1544
10.1126/science.283.5407.1544
Pubmed Abstract
CrossRef
Google Scholar
28.
Charbonneau
Tonks
NK
Kumar
Diltz
CD
Harrylock
Cool
DE
et al
Human placenta protein-tyrosine-phosphatase: amino acid sequence and relationship to a family of receptor-like proteins
Proc Natl Acad Sci U S A
. (
1989
86
5252
10.1073/pnas.86.14.5252
Pubmed Abstract
CrossRef
Google Scholar
29.
Villamar-Cruz
Loza-Mejía
MA
Arias-Romero
LE
Camacho-Arroyo
Recent advances in PTP1B signaling in metabolism and cancer
Biosci Rep
2021
41
11
):
BSR20211994
10.1042/BSR20211994
Pubmed Abstract
CrossRef
Google Scholar
30.
Montalibet
Kennedy
BP
Therapeutic strategies for targeting PTP1B in diabetes
Drug Discovery Today: Therapeutic Strategies
. (
2005
129
35
10.1016/j.ddstr.2005.05.002
CrossRef
Google Scholar
31.
Röder
PV
Wu
Liu
Han
Pancreatic regulation of glucose homeostasis
Exp Mol Med
. (
2016
48
e219
10.1038/emm.2016.6
CrossRef
Google Scholar
32.
Roh
Song
DK
Kim
MS
Emerging role of the brain in the homeostatic regulation of energy and glucose metabolism
Exp Mol Med
2016
48
e216
10.1038/emm.2016.4
Pubmed Abstract
CrossRef
Google Scholar
33.
Freeman
AM
Acevedo
LA
Pennings
Insulin resistance
. In:
StatPearls
Treasure Island, FL
StatPearls Publishing
2024
).
Google Scholar
34.
Fazakerley
DJ
Krycer
JR
Kearney
AL
Hocking
SL
James
DE
Muscle and adipose tissue insulin resistance: malady without mechanism?
J Lipid Res
2019
60
1720
32
10.1194/jlr.R087510
Pubmed Abstract
CrossRef
Google Scholar
35.
Haeusler
RA
Mcgraw
TE
Accili
Biochemical and cellular properties of insulin receptor signalling
Nat Rev Mol Cell Biol
. (
2018
19
31
44
10.1038/nrm.2017.89
Pubmed Abstract
CrossRef
Google Scholar
36.
Fu
Shi
West
TM
Xiang
YK
Cross-talk between insulin signaling and G protein–coupled receptors
J Cardiovasc Pharmacol
. (
2017
70
):
74
86
10.1097/FJC.0000000000000481
Pubmed Abstract
CrossRef
Google Scholar
37.
Schultze
SM
Hemmings
BA
Niessen
Tschopp
PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis
Expert Rev Mol Med
. (
2012
14
e1
10.1017/S1462399411002109
Pubmed Abstract
CrossRef
Google Scholar
38.
Peterson
Chandler
HL
Insulin facilitates corneal wound healing in the diabetic environment through the RTK-PI3K/akt/mTOR axis
in vitro
Mol Cell Endocrinol
2022
548
111611
10.1016/j.mce.2022.111611
Pubmed Abstract
CrossRef
Google Scholar
39.
Klaman
LD
Boss
Peroni
OD
Kim
JK
Martino
JL
Zabolotny
JM
et al
Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice
Mol Cell Biol
2000
20
5479
89
10.1128/MCB.20.15.5479-5489.2000
Pubmed Abstract
CrossRef
Google Scholar
40.
Münzberg
Björnholm
Bates
SH
Myers
MG
JR
Leptin receptor action and mechanisms of leptin resistance
Cell Mol Life Sci
2005
62
642
52
10.1007/s00018-004-4432-1
CrossRef
Google Scholar
41.
Seth
Biswas
Ganguly
Chakrabarti
Chaudhuri
AG
Leptin and obesity
Physiol Int
. (
2020
107
455
68
10.1556/2060.2020.00038
Pubmed Abstract
CrossRef
Google Scholar
42.
Sopjani
Morina
Uka
Xuan
NT
Dërmaku-Sopjani
JAK2-mediated intracellular signaling
Curr Mol Med
. (
2021
21
417
25
10.2174/1566524020666201015144702
Pubmed Abstract
CrossRef
Google Scholar
43.
Xu
AW
Kaelin
CB
Takeda
Akira
Schwartz
MW
Barsh
GS
PI3K Integrates the action of insulin and leptin on hypothalamic neurons
J Clin Invest
. (
2005
115
951
10.1172/JCI24301
Pubmed Abstract
CrossRef
Google Scholar
44.
Bjørbaek
Buchholz
RM
Davis
SM
Bates
SH
Pierroz
DD
Gu
et al
Divergent roles of SHP-2 in ERK activation by leptin receptors
J Biol Chem
. (
2001
276
4747
55
10.1074/jbc.M007439200
CrossRef
Google Scholar
45.
Zhang
EE
Chapeau
Hagihara
Feng
GS
Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism
Proc Natl Acad Sci U S A
2004
101
16064
10.1073/pnas.0405041101
Pubmed Abstract
CrossRef
Google Scholar
46.
Hahn
TM
Breininger
JF
Baskin
DG
Schwartz
MW
Coexpression of AGRP and NPY in fasting-activated hypothalamic neurons
Nat Neurosci
1998
271
10.1038/1082
Pubmed Abstract
CrossRef
Google Scholar
47.
Cook
WS
Unger
RH
Protein tyrosine phosphatase 1B: a potential leptin resistance factor of obesity
Dev Cell
. (
2002
385
10.1016/S1534-5807(02)00158-2
Pubmed Abstract
CrossRef
Google Scholar
48.
Zabolotny
JM
Bence-Hanulec
KK
Stricker-Krongrad
Haj
Wang
Minokoshi
et al
PTP1B regulates leptin signal transduction in vivo
Dev Cell
2002
489
95
10.1016/S1534-5807(02)00148-X
Pubmed Abstract
CrossRef
Google Scholar
49.
Lembertas
AV
Pérusse
Chagnon
YC
Fisler
JS
Warden
CH
Purcell-Huynh
DA
et al
Identification of an obesity quantitative trait locus on mouse chromosome 2 and evidence of linkage to body fat and insulin on the human homologous region 20q
J Clin Invest
1997
100
1240
10.1172/JCI119637
Pubmed Abstract
CrossRef
Google Scholar
50.
Brown-Shimer
Johnson
KA
Lawrence
JB
Johnson
Bruskin
Green
NR
et al
Molecular cloning and chromosome mapping of the human gene encoding protein phosphotyrosyl phosphatase 1B
Proc Natl Acad Sci USA
. (
1990
87
5148
52
10.1073/pnas.87.13.5148
Pubmed Abstract
CrossRef
Google Scholar
51.
Mok
Cao
Zinman
Hanley
AJG
Harris
SB
Kennedy
BP
et al
A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose tolerance in Oji-Cree
J Clin Endocrinol Metab
2002
87
724
10.1210/jcem.87.2.8253
Pubmed Abstract
CrossRef
Google Scholar
52.
Di Paola
Frittitta
Miscio
Bozzali
Baratta
Centra
et al
A variation in 3′ UTR of hPTP1B increases specific gene expression and associates with insulin resistance
Am J Hum Genet
. (
2002
70
806
12
10.1086/339270
Pubmed Abstract
CrossRef
Google Scholar
53.
Yamakage
Konishi
Muranaka
Hotta
Miyamoto
Morisaki
et al
Association of protein tyrosine phosphatase 1B gene polymorphism with the effects of weight reduction therapy on bodyweight and glycolipid profiles in obese patients
J Diabetes Investig
2021
12
1462
70
10.1111/jdi.13492
Pubmed Abstract
CrossRef
Google Scholar
54.
Le Sommer
Morrice
Pesaresi
Thompson
Vickers
MA
Murray
GI
et al
Deficiency in protein tyrosine phosphatase PTP1B shortens lifespan and leads to development of acute leukemia
Cancer Res
. (
2018
78
75
87
10.1158/0008-5472.CAN-17-0946
Pubmed Abstract
CrossRef
Google Scholar
55.
Kenner
KA
Anyanwu
Olefsky
JM
Kusari
Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling
J Biol Chem
1996
271
19810
10.1074/jbc.271.33.19810
Pubmed Abstract
CrossRef
Google Scholar
56.
Delibegovic
Bence
KK
Mody
Hong
EG
Ko
HJ
Kim
JK
et al
Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase 1B
Mol Cell Biol
. (
2007
27
7727
34
10.1128/MCB.00959-07
Pubmed Abstract
CrossRef
Google Scholar
57.
Bence
KK
Delibegovic
Xue
Gorgun
CZ
Hotamisligil
GS
Neel
BG
et al
Neuronal PTP1B regulates body weight, adiposity and leptin action
Nat Med
. (
2006
12
917
24
10.1038/nm1435
Pubmed Abstract
CrossRef
Google Scholar
58.
Owen
Czopek
Agouni
Grant
Judson
Lees
EK
et al
Adipocyte-specific protein tyrosine phosphatase 1B deletion increases lipogenesis, adipocyte cell size and is a minor regulator of glucose homeostasis
PLoS One
2012
e32700
10.1371/journal.pone.0032700
Pubmed Abstract
CrossRef
Google Scholar
59.
Swarbrick
MM
Havel
PJ
Levin
AA
Bremer
AA
Stanhope
KL
Butler
et al
Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys
Endocrinology
. (
2009
150
1670
10.1210/en.2008-0885
Pubmed Abstract
CrossRef
Google Scholar
60.
Ozek
Kanoski
SE
Zhang
ZY
Grill
HJ
Bence
KK
Protein-tyrosine phosphatase 1B (PTP1B) is a novel regulator of central brain-derived neurotrophic factor and tropomyosin receptor kinase B (TrkB) signaling
J Biol Chem
2014
289
31682
92
10.1074/jbc.M114.603621
Pubmed Abstract
CrossRef
Google Scholar
61.
Banno
Zimmer
De Jonghe
BC
Atienza,
Rak
Yang
et al
PTP1B and SHP2 in POMC neurons reciprocally regulate energy balance in mice
J Clin Invest
. (
2010
120
720
34
10.1172/JCI39620
Pubmed Abstract
CrossRef
Google Scholar
62.
Haj
FG
Zabolotny
JM
Kim
YB
Kahn
BB
Neel
BG
Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B-/-mice
J Biol Chem
2005
280
15038
46
10.1074/jbc.M413240200
Pubmed Abstract
CrossRef
Google Scholar
63.
Delibegovic
Zimmer
Kauffman
Rak
Hong
EG
Cho
YR
et al
Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress
Diabetes
. (
2009
58
590
10.2337/db08-0913
Pubmed Abstract
CrossRef
Google Scholar
64.
Vercauteren
Remy
Devaux
Dautreaux
Henry
JP
Bauer
et al
Improvement of peripheral endothelial dysfunction by protein tyrosine phosphatase inhibitors in heart failure
Circulation
2006
114
2498
507
10.1161/CIRCULATIONAHA.106.630129
Pubmed Abstract
CrossRef
Google Scholar
65.
Gogiraju
Schroeter
MR
Bochenek
ML
Hubert
Münzel
Hasenfuss
et al
Endothelial deletion of protein tyrosine phosphatase-1B protects against pressure overload-induced heart failure in mice
Cardiovasc Res
. (
2016
111
204
16
10.1093/cvr/cvw101
Pubmed Abstract
CrossRef
Google Scholar
66.
Lanahan
AA
Lech
Dubrac
Zhang
Zhuang
ZW
Eichmann
et al
PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells
Circulation
. (
2014
130
902
10.1161/CIRCULATIONAHA.114.009683
Pubmed Abstract
CrossRef
Google Scholar
67.
Figueiredo
Figueroa
ALC
Garcia
Fernandez-Ruiz
Broca
Wojtusciszyn
et al
Targeting pancreatic islet PTP1B improves islet graft revascularization and transplant outcomes
Sci Transl Med
. (
2019
11
497
):
eaar6294
10.1126/scitranslmed.aar6294
Pubmed Abstract
CrossRef
Google Scholar
68.
Salmeen
Andersen
JN
Myers
MP
Tonks
NK
Barford
Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B
Mol Cell
. (
2000
1401
12
10.1016/S1097-2765(00)00137-4
Pubmed Abstract
CrossRef
Google Scholar
69.
Bettaieb
Bakke
Nagata
Matsuo
Xi
Liu
et al
Protein tyrosine phosphatase 1B regulates pyruvate kinase M2 tyrosine phosphorylation
J Biol Chem
. (
2013
288
17360
71
10.1074/jbc.M112.441469
Pubmed Abstract
CrossRef
Google Scholar
70.
Matsuo
Bettaieb
Nagata
Matsuo
Keilhack
Haj
FG
Regulation of brown fat adipogenesis by protein tyrosine phosphatase 1B
PLoS One
. (
2011
e16446
10.1371/journal.pone.0016446
Pubmed Abstract
CrossRef
Google Scholar
71.
Miranda
González-Rodríguez
Revuelta-Cervantes
Rondinone
CM
ValverdE
ÁM
Beneficial effects of PTP1B deficiency on brown adipocyte differentiation and protection against apoptosis induced by pro- and anti-inflammatory stimuli
Cell Signal
2010
22
645
59
10.1016/j.cellsig.2009.11.019
Pubmed Abstract
CrossRef
Google Scholar
72.
Bruder-Nascimento
Butler
BR
Herren
DJ
Brands
MW
Bence
KK
Belin De Chantemèle
EJ
Deletion of protein tyrosine phosphatase 1b in proopiomelanocortin neurons reduces neurogenic control of blood pressure and protects mice from leptin- and sympatho-mediated hypertension
Pharmacol Res
. (
2015
102
235
44
10.1016/j.phrs.2015.10.012
Pubmed Abstract
CrossRef
Google Scholar
73.
Vanevski
Xu
Molecular and neural bases underlying roles of BDNF in the control of body weight
Front Neurosci
2013
37
10.3389/fnins.2013.00037
Pubmed Abstract
CrossRef
Google Scholar
74.
Ohira
Hayashi
A new aspect of the TrkB signaling pathway in neural plasticity
Curr Neuropharmacol
. (
2009
276
85
10.2174/157015909790031210
Pubmed Abstract
CrossRef
Google Scholar
75.
Van Gaal
LF
Mertens
IL
De Block
CE
Mechanisms linking obesity with cardiovascular disease
Nature
2006
444
875
80
10.1038/nature05487
Pubmed Abstract
CrossRef
Google Scholar
76.
Wyatt
SB
Winters
KP
Dubbert
PM
Overweight and obesity: prevalence, consequences, and causes of a growing public health problem
Am J Med Sci
2006
331
166
74
10.1097/00000441-200604000-00002
Pubmed Abstract
CrossRef
Google Scholar
77.
Din-Dzietham
Liu
Bielo
MV
Shamsa
High blood pressure trends in children and adolescents in national surveys, 1963 to 2002
Circulation
. (
2007
116
1488
96
10.1161/CIRCULATIONAHA.106.683243
Pubmed Abstract
CrossRef
Google Scholar
78.
Schramm
Fine
DM
Edwards
MA
Reeb
AN
Krenz
The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling
Am J Physiol Heart Circ Physiol
. (
2012
302
H231
43
10.1152/ajpheart.00665.2011
Pubmed Abstract
CrossRef
Google Scholar
79.
Nguyen
TD
Schwarzer
Schrepper
Amorim
PA
Blum
Hain
et al
Increased protein tyrosine phosphatase 1B (PTP1B) activity and cardiac insulin resistance precede mitochondrial and contractile dysfunction in pressure-overloaded hearts
J Am Heart Assoc
. (
2018
e008865
10.1161/JAHA.118.008865
Pubmed Abstract
CrossRef
Google Scholar
80.
Fang
CX
Doser
TA
Yang
Sreejayan
Ren
Metallothionein antagonizes aging-induced cardiac contractile dysfunction: role of PTP1B, insulin receptor tyrosine phosphorylation and AKT
Aging Cell
2006
177
85
10.1111/j.1474-9726.2006.00201.x
Pubmed Abstract
CrossRef
Google Scholar
81.
Wade
Belhaj
Poizat
Protein tyrosine phosphatases in cardiac physiology and pathophysiology
Heart Fail Rev
2018
23
261
72
10.1007/s10741-018-9676-1
Pubmed Abstract
CrossRef
Google Scholar
82.
Hamilton
SJ
Watts
GF
Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment
Rev Diabet Stud
2013
10
133
56
10.1900/RDS.2013.10.133
Pubmed Abstract
CrossRef
Google Scholar
83.
Shi
Vanhoutte
PM
Macro- and microvascular endothelial dysfunction in diabetes
J Diabetes
. (
2017
434
49
10.1111/1753-0407.12521
Pubmed Abstract
CrossRef
Google Scholar
84.
Unemori
EN
Ferrara
Bauer
EA
Amento
EP
Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells
J Cell Physiol
1992
153
557
62
10.1002/jcp.1041530317
Pubmed Abstract
CrossRef
Google Scholar
85.
Hu
GJ
Feng
YG
Lu
WP
Li
HT
Xie
HW
Li
SF
Effect of combined VEGF(165)/SDF-1 gene therapy on vascular remodeling and blood perfusion in cerebral ischemia
J Neurosurg
. (
2017
127
670
10.3171/2016.9.JNS161234
Pubmed Abstract
CrossRef
Google Scholar
86.
Schalkwijk
CG
Stehouwer
CD
Vascular complications in diabetes mellitus: the role of endothelial dysfunction
Clin Sci (Lond)
2005
109
143
59
10.1042/CS20050025
Pubmed Abstract
CrossRef
Google Scholar
87.
Luo
Zheng
Jiang
Li
Guo
Wang
et al
Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from rhodomela confervoides
Br J Pharmacol
2020
177
4464
80
10.1111/bph.15195
Pubmed Abstract
CrossRef
Google Scholar
88.
Kingwell
BA
Nitric oxide as a metabolic regulator during exercise: effects of training in health and disease
Clin Exp Pharmacol Physiol
2000
27
239
50
10.1046/j.1440-1681.2000.03232.x
Pubmed Abstract
CrossRef
Google Scholar
89.
Braile
Marcella
Cristinziano
Galdiero
MR
Modestino
Ferrara
AL
et al
VEGF-A in cardiomyocytes and heart diseases
Int J Mol Sci
. (
2020
21
15
):
5294
10.3390/ijms21155294
Pubmed Abstract
CrossRef
Google Scholar
90.
Peach
CJ
Mignone
VW
Arruda
MA
Alcobia
DC
Hill
SJ
Kilpatrick
LE
et al
Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2
Int J Mol Sci
. (
2018
19
):
1264
10.3390/ijms19041264
Pubmed Abstract
CrossRef
Google Scholar
91.
Zhou
Zhu
Cui
Shi
Yuan
Shi
et al
The role of the VEGF family in coronary heart disease
Front Cardiovasc Med
2021
738325
10.3389/fcvm.2021.738325
Pubmed Abstract
CrossRef
Google Scholar
92.
Koch
Claesson-Welsh
Signal transduction by vascular endothelial growth factor receptors
Cold Spring Harb Perspect Med
2012
a006502
10.1101/cshperspect.a006502
Pubmed Abstract
CrossRef
Google Scholar
93.
Besnier
Galaup
Nicol
Henry
JP
Coquerel
Gueret
et al
Enhanced angiogenesis and increased cardiac perfusion after myocardial infarction in protein tyrosine phosphatase 1B-deficient mice
Faseb J
. (
2014
28
3351
61
10.1096/fj.13-245753
Pubmed Abstract
CrossRef
Google Scholar
94.
Nakamura
Patrushev
Inomata
Mehta
Urao
Kim
HW
et al
Role of protein tyrosine phosphatase 1B in vascular endothelial growth factor signaling and cell-cell adhesions in endothelial cells
Circ Res
2008
102
1182
91
10.1161/CIRCRESAHA.107.167080
Pubmed Abstract
CrossRef
Google Scholar
95.
Louis
SF
Zahradka
Vascular smooth muscle cell motility: from migration to invasion
Exp Clin Cardiol
2010
15
e75
85
Pubmed Abstract
Google Scholar
96.
Markova
Herrlich
Rönnstrand
Böhmer
FD
Identification of protein tyrosine phosphatases associating with the PDGF receptor
Biochemistry
2003
42
2691
10.1021/bi0265574
Pubmed Abstract
CrossRef
Google Scholar
97.
Chang
Ceacareanu
Zhuang
Zhang
Pu
Ceacareanu
AC
et al
Counter-regulatory function of protein tyrosine phosphatase 1B in platelet-derived growth factor- or fibroblast growth factor-induced motility and proliferation of cultured smooth muscle cells and in neointima formation
Arterioscler Thromb Vasc Biol
. (
2006
26
501
10.1161/01.ATV.0000201070.71787.b8
Pubmed Abstract
CrossRef
Google Scholar
98.
Sreejayan
Lin
Hassid
NO attenuates insulin signaling and motility in aortic smooth muscle cells via protein tyrosine phosphatase 1B–mediated mechanism.
Arterioscler Thromb Vasc Biol
. (
2002
22
1086
92
10.1161/01.ATV.0000020550.65963.E9
Pubmed Abstract
CrossRef
Google Scholar
99.
Hassid
Huang
Yao
Role of PTP-1B in aortic smooth muscle cell motility and tyrosine phosphorylation of focal adhesion proteins
Am J Physiol
. (
1999
277
H192
10.1152/ajpheart.1999.277.1.H192
Pubmed Abstract
CrossRef
Google Scholar
100.
Zhou
Pu
WT
Recounting cardiac cellular composition
Circ Res
2016
118
368
70
10.1161/CIRCRESAHA.116.308139
Pubmed Abstract
CrossRef
Google Scholar
101.
Giordano
FJ
Gerber
HP
Williams
SP
Vanbruggen
Bunting
Ruiz-Lozano
et al
A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function
Proc Natl Acad Sci U S A
. (
2001
98
5780
10.1073/pnas.091415198
Pubmed Abstract
CrossRef
Google Scholar
102.
Neufeld
Cohen
Gengrinovitch
Poltorak
Vascular endothelial growth factor (VEGF) and its receptors
Faseb J
. (
1999
13
22
10.1096/fasebj.13.1.9
Pubmed Abstract
CrossRef
Google Scholar
103.
Curry
JM
Eubank
TD
Roberts
RD
Wang
Pore
Maity
et al
M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo
PLoS One
. (
2008
e3405
10.1371/journal.pone.0003405
Pubmed Abstract
CrossRef
Google Scholar
104.
Dor
Camenisch
TD
Itin
Fishman
GI
Mcdonald
JA
Carmeliet
et al
A novel role for VEGF in endocardial cushion formation and its potential contribution to congenital heart defects
Development
2001
128
1531
10.1242/dev.128.9.1531
Pubmed Abstract
CrossRef
Google Scholar
105.
Hsieh
PC
Davis
ME
Lisowski
LK
Lee
RT
Endothelial-cardiomyocyte interactions in cardiac development and repair
Annu Rev Physiol
. (
2006
68
51
66
10.1146/annurev.physiol.68.040104.124629
Pubmed Abstract
CrossRef
Google Scholar
106.
Sun
Chanrasekhar
Kessinger
CW
Tang
Gao
Kamli-Salino
et al
Cardiomyocyte-specific deletion of PTP1B protects against HFD-induced cardiomyopathy through direct regulation of cardiac metabolic signaling
bioRxiv
[Preprint] (
2023
). Available at: 10.1101/2023.05.19.541546
Google Scholar
107.
Magadum
Singh
Kurian
AA
Munir
Mehmood
Brown
et al
Pkm2 regulates cardiomyocyte cell cycle and promotes cardiac regeneration
Circulation
2020
141
1249
65
10.1161/CIRCULATIONAHA.119.043067
Pubmed Abstract
CrossRef
Google Scholar
108.
Kandadi
MR
Panzhinskiy
, Roe
ND
Nair
Hu
Sun
Deletion of protein tyrosine phosphatase 1B rescues against myocardial anomalies in high fat diet-induced obesity: role of AMPK-dependent autophagy
Biochim Biophys Acta
2015
1852
299
309
10.1016/j.bbadis.2014.07.004
Pubmed Abstract
CrossRef
Google Scholar
109.
Song
Zhang
Wang
Small interference RNA against PTP-1B reduces hypoxia/reoxygenation induced apoptosis of rat cardiomyocytes
Apoptosis
. (
2008
13
383
93
10.1007/s10495-008-0181-1
Pubmed Abstract
CrossRef
Google Scholar
110.
Coulis
Londhe
AD
Sagabala
RS
Shi
Labbé
DP
Bergeron
et al
Protein tyrosine phosphatase 1B regulates miR-208b-argonaute 2 association and thyroid hormone responsiveness in cardiac hypertrophy
Sci Signal
. (
2022
15
eabn6875
10.1126/scisignal.abn6875
Pubmed Abstract
CrossRef
Google Scholar
111.
Zhou
Schötterl
Backes
Brunner
Hahn
JK
Ionesi
et al
Inhibition of miR-208b improves cardiac function in titin-based dilated cardiomyopathy
Int J Cardiol
2017
230
634
41
10.1016/j.ijcard.2016.12.171
Pubmed Abstract
CrossRef
Google Scholar
112.
Grueter
CE
Van Rooij
Johnson
BA
Deleon
SM
Sutherland
LB
Qi
et al
A cardiac microRNA governs systemic energy homeostasis by regulation of MED13
Cell
. (
2012
149
671
83
10.1016/j.cell.2012.03.029
Pubmed Abstract
CrossRef
Google Scholar
113.
Zhang
Zhang
ZY
PTP1B as a drug target: recent developments in PTP1B inhibitor discovery
Drug Discov Today
2007
12
373
81
10.1016/j.drudis.2007.03.011
Pubmed Abstract
CrossRef
Google Scholar
114.
Abdel-Magid
AF
The inhibitors of protein tyrosine phosphatase nonreceptor type 2 (PTPN2) as potential enhancers of cancer immunotherapy and type 1 (PTPN1) as treatment of metabolic diseases
ACS Med Chem Lett
. (
2022
13
19
21
10.1021/acsmedchemlett.1c00678
Pubmed Abstract
CrossRef
Google Scholar
115.
Liu
Mathieu
Berthelet
Zhang
Dupret
JM
Rodrigues Lima
Human protein tyrosine phosphatase 1B (PTP1B): from structure to clinical inhibitor perspectives
Int J Mol Sci
2022
23
13
):
7027
10.3390/ijms23137027
Pubmed Abstract
CrossRef
Google Scholar
116.
Sharma
Xie
Yang
Wang
Zhou
Xiang
et al
Recent advance on PTP1B inhibitors and their biomedical applications
Eur J Med Chem
2020
199
112376
10.1016/j.ejmech.2020.112376
Pubmed Abstract
CrossRef
Google Scholar
117.
Krishnan
Koveal
Miller
DH
Xue
Akshinthala
SD
Kragelj
et al
Targeting the disordered C terminus of PTP1B with an allosteric inhibitor
Nat Chem Biol
. (
2014
10
558
66
10.1038/nchembio.1528
Pubmed Abstract
CrossRef
Google Scholar
118.
Lantz
KA
Hart
SG
Planey
SL
Roitman
MF
Ruiz-White
IA
Wolfe
HR
et al
Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in diet-induced obese mice
Obesity (Silver Spring)
. (
2010
18
1516
23
10.1038/oby.2009.444
Pubmed Abstract
CrossRef
Google Scholar
119.
Geary
RS
Bradley
JD
Watanabe
Kwon
Wedel
Van Lier
JJ
et al
Lack of pharmacokinetic interaction for ISIS 113715, a 2′-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone
Clin Pharmacokinet
. (
2006
45
789
801
10.2165/00003088-200645080-00003
Pubmed Abstract
CrossRef
Google Scholar
120.
Waring
JF
Ciurlionis
Clampit
JE
Morgan
Gum
RJ
Jolly
RA
et al
PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat
Mol Cell Endocrinol
. (
2003
203
155
68
10.1016/S0303-7207(03)00008-X
Pubmed Abstract
CrossRef
Google Scholar
121.
Digenio
Pham
NC
Watts
LM
Morgan
ES
Jung
SW
Baker
BF
et al
Antisense inhibition of protein tyrosine phosphatase 1B with IONIS-PTP-1BRx improves insulin sensitivity and reduces weight in overweight patients with type 2 diabetes
Diabetes Care
2018
41
807
14
10.2337/dc17-2132
Pubmed Abstract
CrossRef
Google Scholar
122.
Krishnan
Felice
Rivera
Pappin
DJ
Tonks
NK
DPM-1001 decreased copper levels and ameliorated deficits in a mouse model of Wilson’s disease
Genes Dev
. (
2018
32
944
52
10.1101/gad.314658.118
Pubmed Abstract
CrossRef
Google Scholar
123.
Kafle
Aher
NG
Khadka
Park
Cho
Isoxazol-5(4H)one derivatives as PTP1B inhibitors showing an anti-obesity effect
Chemi Asian J
. (
2011
2073
10.1002/asia.201100154
CrossRef
Google Scholar
124.
Fordahl
SC
Jones
SR
High-fat-diet-induced deficits in dopamine terminal function are reversed by restoring insulin signaling
ACS Chem Neurosci
2017
290
10.1021/acschemneuro.6b00308
Pubmed Abstract
CrossRef
Google Scholar
125.
Du
ZD
Hu
LT
Zhao
GQ
Li
Ma
ZZ
Protein tyrosine phosphatase 1B regulates the activity of retinal pigment epithelial cells
Mol Vis
. (
2015
21
523
31
Pubmed Abstract
Google Scholar
126.
Du
Dong
Tan
Tan
Zhang
Zhang
et al
Tubeimoside I inhibits cell proliferation and induces a partly disrupted and cytoprotective autophagy through rapidly hyperactivation of MEK1/2-ERK1/2 cascade via promoting PTP1B in melanoma
Front Cell Dev Biol
. (
2020
607757
10.3389/fcell.2020.607757
Pubmed Abstract
CrossRef
Google Scholar
127.
Ponnusamy
Ma
Zhuang
Necrotic renal epithelial cell inhibits renal interstitial fibroblast activation: role of protein tyrosine phosphatase 1B
Am J Physiol Renal Physiol
. (
2013
304
F698
709
10.1152/ajprenal.00564.2012
Pubmed Abstract
CrossRef
Google Scholar
128.
Xue
Tian
Wang
XS
Xia
Wu
Discovery of potent PTP1B inhibitors via structure-based drug design, synthesis and in vitro bioassay of norathyriol derivatives
Bioorg Chem
. (
2019
86
224
34
10.1016/j.bioorg.2019.01.059
Pubmed Abstract
CrossRef
Google Scholar
129.
Erbe
DV
Wang
Zhang
YL
Harding
Kung
Tam
et al
Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms
Mol Pharmacol
2005
67
69
77
10.1124/mol.104.005553
Pubmed Abstract
CrossRef
Google Scholar
130.
Zhang
ZY
Lee
SY
PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity
Expert Opin Investig Drugs
2003
12
223
33
10.1517/13543784.12.2.223
Pubmed Abstract
CrossRef
Google Scholar
131.
Matulis
Kranz
JK
Salemme
FR
Todd
MJ
Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor
Biochemistry
. (
2005
44
5258
66
10.1021/bi048135v
Pubmed Abstract
CrossRef
Google Scholar
132.
Weber
PC
Salemme
FR
Applications of calorimetric methods to drug discovery and the study of protein interactions
Curr Opin Struct Biol
2003
13
115
21
10.1016/S0959-440X(03)00003-4
Pubmed Abstract
CrossRef
Google Scholar
133.
Kumar
GS
Page
Peti
The mode of action of the protein tyrosine phosphatase 1B inhibitor ertiprotafib
PLoS One
. (
2020
15
e0240044
10.1371/journal.pone.0240044
Pubmed Abstract
CrossRef
Google Scholar
134.
Rao
MN
Shinnar
AE
Noecker
LA
Chao
TL
Feibush
Snyder
et al
Aminosterols from the dogfish shark squalus acanthias
J Nat Prod
2000
63
631
10.1021/np990514f
Pubmed Abstract
CrossRef
Google Scholar
135.
Julien
SG
Tremblay
ML
Chapter 99—insulin receptor PTP: pTP1B
. In:
Bradshaw
RA
Dennis
EA
, editors.
Handbook of Cell Signaling
2nd ed
San Diego
Academic Press
2010
).
Google Scholar
136.
Liu
Chen
Hu
Gao
Zeng
Cheng
et al
PTP1B inhibition improves mitochondrial dynamics to alleviate calcific aortic valve disease via regulating OPA1 homeostasis
JACC Basic Transl Sci
. (
2022
697
712
10.1016/j.jacbts.2022.03.002
Pubmed Abstract
CrossRef
Google Scholar
137.
Fukuda
Ohta
Sakata
Morinaga
Ito
Nakagawa
et al
Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551
Diabetes Obes Metab
. (
2010
12
299
306
10.1111/j.1463-1326.2009.01162.x
Pubmed Abstract
CrossRef
Google Scholar
138.
Qian
Zhang
He
Wang
Liu
Recent advances in the development of protein tyrosine phosphatase 1B inhibitors for type 2 diabetes
Future Med Chem
. (
2016
1239
58
10.4155/fmc-2016-0064
Pubmed Abstract
CrossRef
Google Scholar
139.
Krishnan
Konidaris
KF
Gasser
Tonks
NK
A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models
J Biol Chem
. (
2018
293
1517
25
10.1074/jbc.C117.819110
Pubmed Abstract
CrossRef
Google Scholar
140.
Phong
NV
Oanh
VT
Yang
SY
Choi
JS
Min
BS
Kim
JA
PTP1B inhibition studies of biological active phloroglucinols from the rhizomes of dryopteris crassirhizoma: kinetic properties and molecular docking simulation
Int J Biol Macromol
. (
2021
188
719
28
10.1016/j.ijbiomac.2021.08.091
Pubmed Abstract
CrossRef
Google Scholar
141.
Ha
MT
Seong
SH
Nguyen
TD
Cho
WK
Ah
KJ
Ma
JY
et al
Chalcone derivatives from the root bark of morus alba L. Act as inhibitors of PTP1B and α-glucosidase
Phytochemistry
. (
2018
155
114
25
10.1016/j.phytochem.2018.08.001
Pubmed Abstract
CrossRef
Google Scholar
142.
Fukada
Tonks
NK
The reciprocal role of Egr-1 and Sp family proteins in regulation of the PTP1B promoter in response to the p210 Bcr-abl oncoprotein-tyrosine kinase
J Biol Chem
. (
2001
276
25512
10.1074/jbc.M101354200
Pubmed Abstract
CrossRef
Google Scholar
143.
Fukada
Tonks
NK
Identification of YB-1 as a regulator of PTP1B expression: implications for regulation of insulin and cytokine signaling
EMBO J
2003
22
479
93
10.1093/emboj/cdg067
Pubmed Abstract
CrossRef
Google Scholar
144.
Zabolotny
JM
Kim
YB
Welsh
LA
Kershaw
EE
Neel
BG
Kahn
BB
Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo
J Biol Chem
2008
283
14230
41
10.1074/jbc.M800061200
Pubmed Abstract
CrossRef
Google Scholar
145.
Suwaki
Vanhecke
Atkins
KM
GraF
Swabey
Huang
et al
A HIF-regulated VHL-PTP1B-src signaling axis identifies a therapeutic target in renal cell carcinoma
Sci Transl Med
. (
2011
85ra47
10.1126/scitranslmed.3002004
Pubmed Abstract
CrossRef
Google Scholar
146.
Rehman
Akash
MS
Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked?
J Biomed Sci
. (
2016
23
87
10.1186/s12929-016-0303-y
Pubmed Abstract
CrossRef
Google Scholar
147.
Zhang
Han
Tang
Wu
Qu
Shen
miR-744 enhances type I interferon signaling pathway by targeting PTP1B in primary human renal mesangial cells
Sci Rep
2015
12987
10.1038/srep12987
Pubmed Abstract
CrossRef
Google Scholar
148.
Yang
YM
Seo
SY
Kim
TH
Kim
SG
Decrease of microRNA-122 causes hepatic insulin resistance by inducing protein tyrosine phosphatase 1B, which is reversed by licorice flavonoid
Hepatology
. (
2012
56
2209
20
10.1002/hep.25912
Pubmed Abstract
CrossRef
Google Scholar
149.
Sun
Yu
Yu
Liu
Zhou
Liu
et al
miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B
Cell Death Dis
. (
2018
522
10.1038/s41419-018-0611-0
Pubmed Abstract
CrossRef
Google Scholar
150.
Yu
Liu
Liu
Zhou
Sun
Liu
et al
PTP1B markedly promotes breast cancer progression and is regulated by miR-193a-3p
FEBS J
. (
2019
286
1136
53
10.1111/febs.14724
Pubmed Abstract
CrossRef
Google Scholar
151.
Wang
Cheng
Chen
Xue
microRNA-135a protects against myocardial ischemia-reperfusion injury in rats by targeting protein tyrosine phosphatase 1B
J Cell Biochem
2019
120
10421
33
10.1002/jcb.28327
Pubmed Abstract
CrossRef
Google Scholar
152.
Xu
Zhang
Chen
Yang
Yin J
miR-146b regulates cell proliferation and apoptosis in gastric cancer by targeting PTP1B
Dig Dis Sci
. (
2020
65
457
63
10.1007/s10620-019-05771-8
Pubmed Abstract
CrossRef
Google Scholar
153.
Galic
Klingler-Hoffmann
Fodero-Tavoletti
MT
Puryer
MA
Meng
TC
Tonks
NK
et al
Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP
Mol Cell Biol
. (
2003
23
2096
108
10.1128/MCB.23.6.2096-2108.2003
Pubmed Abstract
CrossRef
Google Scholar
154.
Gorgulla
Boeszoermenyi
Wang
ZF
Fischer
PD
Coote
PW
Padmanabha Das
KM
et al
An open-source drug discovery platform enables ultra-large virtual screens
Nature
. (
2020
580
663
10.1038/s41586-020-2117-z
Pubmed Abstract
CrossRef
Google Scholar
155.
Adams
Thornton
BP
Tabernero
A new paradigm for KIM-PTP drug discovery: identification of allosteric sites with potential for selective inhibition using virtual screening and LEI analysis
Int J Mol Sci
. (
2021
22
22
):
12206
10.3390/ijms222212206
Pubmed Abstract
CrossRef
Google Scholar
156.
Mullard
DNA tags help the hunt for drugs
Nature
2016
530
367
10.1038/530367a
Pubmed Abstract
CrossRef
Google Scholar
157.
Burslem
GM
Crews
CM
Proteolysis-targeting chimeras as therapeutics and tools for biological discovery
Cell
. (
2020
181
102
14
10.1016/j.cell.2019.11.031
Pubmed Abstract
CrossRef
Google Scholar
158.
Feng
Dong
Shang
Zhang
Crans
DC
Yang
Convergent protein phosphatase inhibitor design for PTP1B and TCPTP: exchangeable vanadium coordination complexes on graphene quantum dots
Adv Funct Mater
2022
32
2108645
10.1002/adfm.202108645
CrossRef
Google Scholar
159.
Gunasekaran
Haile
Nigusse
Dhanaraju
MD
Nanotechnology: an effective tool for enhancing bioavailability and bioactivity of phytomedicine
Asian Pac J Trop Biomed
. (
2014
S1
10.12980/APJTB.4.2014C980
Pubmed Abstract
CrossRef
Google Scholar
160.
Ghosh
Watanabe
RM
Hauser
ER
Valle
Magnuson
VL
Erdos
MR
et al
Type 2 diabetes: evidence for linkage on chromosome 20 in 716 Finnish affected sib pairs
Proc Natl Acad Sci USA
. (
1999
96
2198
203
10.1073/pnas.96.5.2198
Pubmed Abstract
CrossRef
Google Scholar
Summary
Keywords
protein tyrosine phosphatase 1B (PTP1B)
cardiovascular disease
insulin resistance
diabetes
obesity
therapeutics
Citation
Sun Y, Dinenno FA, Tang P and Kontaridis MI (2024)
Protein tyrosine phosphatase 1B in metabolic and cardiovascular diseases: from mechanisms to therapeutics
Front. Cardiovasc. Med.
11:1445739. doi:
10.3389/fcvm.2024.1445739
Received
11 June 2024
Accepted
05 August 2024
Published
22 August 2024
Volume
11 - 2024
Edited by
Venkatesh Sundararajan, West Virginia University, United States
Reviewed by
Marcello Rota, New York Medical College, United States
Sujith Rajan, New York University, United States
Updates
This is an open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY)
. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Correspondence:
Maria I. Kontaridis
mkontaridis@mmri.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Article metrics
View details
PDF
ReadCube
EPUB
XML
High-impact AI
AI playbook for researchers
Your step by step support for responsible and impactful AI use
Explore the guide
Outline
Figures
Cite article
Copy to clipboard
Export citation file
BibTex
EndNote
Reference Manager
Simple Text file
Share article
Email
WeChat
Share on WeChat
Scan with WeChat to share this article
Article metrics